RGNXREGENXBIO Inc.

1. Sep 23, 2026On September 23, 2026, REGENXBIO Inc. (the “Company”) and The Trustees of the University of Pennsylvania (“UPenn”) entered into a Settlement Agreement (the “Settlement Agreement”) with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC (together with Sarepta Therapeutics, Inc., “Sarepta”) and Catalent …Material agreement entered · Form 8-K
2. Aug 25, 2026On August 25, 2026, the Board of Directors (the “Board”) of REGENXBIO Inc. (the “Company”), elected Gregory Ciongoli as a Class II director of the Company effective immediately.Director or officer change · Form 8-K
3. Aug 24, 2026On August 24, 2026, the Company announced that it received communication from the FDA that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for MPS II was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 BLA in the near term.Regulation FD disclosure · Form 8-K
4. Aug 6, 2026REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights.Earnings release · press release
5. Jul 20, 2026On July 16, 2026, REGENXBIO Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein (collectively, the …Other event · Form 8-K
6. Jun 29, 2026On June 29, 2026, REGENXBIO Inc. (the “Company”) announced that it has earned a milestone payment of $100.0 million from AbbVie Global Enterprises Ltd. (“AbbVie”), a subsidiary of AbbVie Inc., pursuant to the Collaboration and License Agreement, dated as of September 10, 2021 between the Company and AbbVie, as amended …Other event · Form 8-K
7. Jun 3, 2026On June 3, 2026, the Company commenced a Stock Option Exchange Program for non-executive employees that was approved by shareholders at the Annual Meeting.Shareholder vote results · Form 8-K
8. May 14, 2026On May 14, 2026, the Company issued a press release announcing topline and interim analysis of data from the AFFINITY DUCHENNE RGX-202 trial (the “RGX-202 Press Release”)Earnings release · Form 8-K
9. Mar 20, 2026On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended …Material agreement entered · Form 8-K
10. Mar 5, 2026REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights.Earnings release · press release
11. Feb 10, 2026On February 7, 2026, the Company received a CRL from the FDA regarding the Company’s BLA for RGX-121, the Company's investigational gene therapy for Mucopolysaccharidosis type II.Regulation FD disclosure · Form 8-K
12. Jan 28, 2026On January 28, 2026, REGENXBIO Inc. (the “Company”) announced that it received communication from the U.S. Food and Drug Administration (“FDA”) that the Company’s Investigational New Drug applications for both its Phase I/II trial evaluating RGX-111 for Mucopolysaccharidosis type I and its Phase I/II/III trial of …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.